SGLT2 Inhibition in Heart Failure: New Updates

Published: 08 February 2023

  • Views:

    Views Icon 10491

  • Likes:

    Heart Icon 7
  • episode_image
    12m 35s
    Part 10 Panel Discussion
    Harriette Van Spall, Nandini Gupta, Scott Solomon, Muthiah Vaduganathan, Orly Vardeny, Eileen O’Meara
  • episode_image
    15m 19s
    Part 5 Panel Discussion Harriette Van Spall, Nandini Gupta, Subodh Verma, John JV McMurray, Xiaowen “Wendy” Wang, Pardeep Jhund
Average (ratings)
No ratings
Your rating

Overview

This on-demand version of the live broadcast provides the latest updates on SGLT2 Inhibition in heart failure.

 

Dr Harriette Van Spall (McMaster University, Hamilton, CA) and Dr Nandini Gupta (Mackenzie Health, Richmond Hill, CA) chair and co-chair the programme, and are joined by an outstanding international faculty for a series of insightful presentations and discussions.

 

Note, the live version of this session was CME accredited; this on-demand version is not.

This programme is supported by an unrestricted educational grant from AstraZeneca.

Learning Objectives

  • To explore the mechanisms of cardiorenal protection with SGLT2 inhibition
  • To examine how the safety-efficacy relationship of SGLT2 inhibitors vary with age, frailty, gender and race
  • To break down how SGLT2 inhibitors can be safely and optimally combined with other heart failure pharmacotherapies
  • To recognise the prognostic value of NT-proBNP in SGLT2 inhibition
  • To assess the merit of ejection fraction in heart failure care

Target Audience

  • Primary Care Physicians
  • Endocrinologists
  • Nephrologists
  • Cardiologists
  • Nurses
  • Pharmacists
  • Dietitians
  • Diabetes Educators

More from this programme

Part 1

Do the Kidneys Hold Clues to the HF Benefits Of SGLT2 Inhibitors?

1 session
Do the Kidneys Hold Clues to the HF Benefits Of SGLT2 Inhibitors? Watch now

Part 2

SGLT2 Inhibition in the Elderly and Frail Patients

1 session
SGLT2 Inhibition in the Elderly and Frail Patients Watch now

Part 3

Gender Differences in Outcomes With SGLT2 Inhibitors

1 session
Gender Differences in Outcomes With SGLT2 Inhibitors Watch now

Part 4

Efficacy and Safety of SGLT2 Inhibitors in Black Patients

1 session
Efficacy and Safety of SGLT2 Inhibitors in Black Patients Watch now

Part 5

Panel Discussion

1 session
Panel Discussion Watch now

Part 6

SGLT2 Inhibition in Patients With Improved EF

1 session
SGLT2 Inhibition in Patients With Improved EF Watch now

Part 7

SGLT2 Inhibition With MRAs and ARNis

1 session
SGLT2 Inhibition With MRAs and ARNis Watch now

Part 8

Does NT-proBNP Affect the Efficacy of SGLT2 Inhibitors?

1 session
Does NT-proBNP Affect the Efficacy of SGLT2 Inhibitors? Watch now

Part 9

Does EF Still Matter in HF Management?

1 session
Does EF Still Matter in HF Management? Watch now

Part 10

Panel Discussion

1 session
Panel Discussion Watch now

Faculty Biographies

Eileen O’Meara

Eileen O’Meara

Professor of Medicine

Dr Eileen O’Meara is Professor at the Department of Medicine at the University of Montreal and practices cardiology at the Montreal Heart Institute.

Dr O’Meara pursued a Fellowship in Heart Failure at the Western Infirmary & Glasgow Royal Infirmary in the UK, and another in Stress Echocardiography and Tissue Doppler at Hôpital Européen Georges Pompidou in Paris. 

Her research focuses on remodeling and fibrosis biomarkers in HF, including cardiac imaging biomarkers; as well as on comorbid conditions that contribute to HF, more specifically diabetes, CKD, and anemia. Dr O’Meara has long been involved in clinical research on HF with preserved ejection fraction (HFpEF) and was the Canadian lead investigator for the TOPCAT and PARAGON-HF trials and co-national lead investigator for the DELIVER trial. 

View full profile